Anavex Reveals Positive Preclinical Results with ANAVEX 2-73 in Fragile X

Anavex Life Sciences Corp.

revealed positive data of ANAVEX 2-73 in an exploratory study in a Fragile X syndrome model presented at the Gordon Research Conference for Fragile X and Autism-Related Disorders, being held June 5-10, 2016 in Mount Snow, VT. According to the company, Fragile X syndrome was the most common form of inherited intellectual disability and the most frequent single gene cause of autism. Anavex Life Sciences' President and CEO, Chritopher Missling, reacted to say, "Our previous results in Rett syndrome, together with the new data in another neurodevelopmental disorder, Fragile X, support our hypothesis that ANAVEX 2-73 has a mechanism of action that could be of interest to investigate clinically in rare disorders like Rett syndrome, Fragile X syndrome, and other Autism Spectrum Disorders, in addition to neurodegenerative diseases such as Alzheimer's disease." Similarly, FRAXA Research Foundation CSO, Michael Tranfaglia, commented, "The ANAVEX 2-73 data in an array of behavioral paradigms in a validated mouse model of Fragile X is very encouraging. The results are promising for both Fragile X syndrome and Autism Spectrum Disorders, since there is an overlap in the clinical as well as in the underlying molecular pathology of the two disorders. We would be very interested in continuing the work with ANAVEX 2-73." The company indicated that dosing of ANAVEX 2-73 for 14 days in a Fragile X syndrome mouse model was followed by a battery of behavioral tests, which were linked to pathophysiological signs of Autism-related disorders and Fragile X syndrome: hyper-locomotion, associative learning, and marble burying. The company added that treatment with ANAVEX 2-73 vastly enhanced all behaviors tested. In the pre-market trading on Monday, the stock traded 0.88 percent higher.